Factors Associated with Dialysis Discontinuation Outside of the Acute Care Setting

Matthew J. Roberts,1 Kirsten L. Johansen,2 Timothy P. Copeland,3 Charles E. McCulloch,4 Sarah Coufal,5 and Elaine Ku3,4,6

KIDNEY360 2: 331–335, 2021. doi: https://doi.org/10.34067/KID.0004312020

Materials and Methods

We performed a retrospective observational study using data from the United States Renal Data System (USRDS) and included adults (age ≥18 years) who started dialysis between January 1, 2005 and December 31, 2015. We excluded patients if they were missing key data such as age, sex, race/ethnicity, region, and initial treatment modality.

We identified patient demographic factors including age (categorized as 18–29 years, 30–65 years, and >65 years), sex, race/ethnicity, US census region (West, South, Northeast, Midwest), median neighborhood income by patient’s home zip code, and calendar year of dialysis initiation. Covariates of interest included cause of ESKD, history of comorbidities (stroke, heart failure, smoking status, hypertension, drug dependence, peripheral arterial disease, coronary artery disease, malignancy, or diabetes), and treatment modality (PD or HD, which was time updated). These key demographic factors and covariates were then used as the primary predictors in our models.

In this study, the primary outcome of interest was death due to discontinuation of dialysis, defined using the CDEATH variable in the patient’s file if “withdrawal” was listed as the primary cause of death. Events were subsequently defined using the RXSTOP variable in RXHIST files. The RXHIST file amalgamates data from Medicare Claims, CROWNWeb, the Center for Medicare and Medicaid (CMS) 2728 form, the CMS Death notification form, and the Organ Procurement Transplant Network Treatment files to update ESKD treatment status over time. The RXSTOP variable indicates the reason why kidney replacement therapy was stopped before death and is derived from the patient’s file. Discontinuation events were censored if they occurred after an acute medical complication, but were considered to be discontinuation from dialysis in a nonacute setting if the decision to stop dialysis was noted to follow access failure, transplant failure, chronic failure to thrive, or other causes according to the RXSTOP variable.

To examine the association between candidate predictors (mentioned above) and the risk of dialysis discontinuation, we used Cox proportional hazards models with time of analysis beginning at the date of dialysis initiation and administrative censoring on December 31, 2017. Patients were censored upon

1Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, Dallas, Texas
2Division of Nephrology, Department of Medicine, Hennepin Healthcare and University of Minnesota, Minneapolis, Minnesota
3Division of Nephrology, Department of Medicine, University of California, San Francisco, California
4Division of Epidemiology and Biostatistics, University of California, San Francisco, California
5College of Letters and Science, University of California, Los Angeles, California
6Division of Pediatric Nephrology, Department of Pediatrics, University of California, San Francisco, California

Correspondence: Matthew J. Roberts, University of Texas Southwestern Medical Center, Department of Anesthesiology and Pain Management, 5323 Harry Hines Blvd., Dallas, TX 75390-9068. Email: matthew.roberts@phhs.org

www.kidney360.org Vol 2 February, 2021

Copyright © 2021 by the American Society of Nephrology
receipt of a transplant or death from other causes besides discontinuation.

Our secondary outcome of interest was early discontinuation, defined as death attributed to stopping dialysis within 1.9 years of dialysis initiation (the median time from dialysis initiation to death among patients discontinuing dialysis during the study period). To examine factors associated with early versus late discontinuation, we used the same Cox model as in the primary analysis, but limited follow-up time to 1.9 years after initiation of dialysis. The model for early discontinuation was adjusted for the same covariates as in our primary analysis.

**Results**

We identified 1,175,252 outpatients who met our inclusion criteria with median follow-up time of 2.8 years (interquartile range [IQR], 1.1–4.9). The cohort was predominantly non-Hispanic White (54%) and treated exclusively with HD (86%) (Table 1).

A total of 29,212 (3%) patients discontinued dialysis, which accounted for 4% of all deaths during the study period. The median time from start of dialysis to its discontinuation was 1.9 years (IQR, 0.66–3.79). Compared with patients treated exclusively with HD, patients treated exclusively with PD had a lower risk of discontinuation (hazard ratio [HR], 0.45; 95% confidence interval [95% CI], 0.42 to 0.49). Additionally, patients who switched from PD to HD had a higher risk of stopping dialysis in comparison to those treated exclusively with PD (HR, 2.73; 95% CI, 2.46 to 3.03). The risk of discontinuation among patients who switched from HD to PD (HR, 1.02; 95% CI, 0.97 to 1.07) was similar to patients treated exclusively with HD (Table 2).

### Table 1. Cohort characteristics

| Variable                                | Discontinued Dialysisa (N=29,212) | Total Cohort (N=1,175,252) |
|-----------------------------------------|------------------------------------|----------------------------|
| Age at first dialysis initiation, yrs,  | 75.0 (66.0, 81.0)                  | 64.0 (54.0, 75.0)          |
| median (IQR)                            |                                    |                            |
| Sex (%)                                 |                                    |                            |
| Male                                    | 53.0                               | 56.8                       |
| Female                                  | 47.0                               | 43.2                       |
| Race (%)                                |                                    |                            |
| Non-Hispanic White                      | 78.1                               | 53.6                       |
| Non-Hispanic Black                      | 13.6                               | 27.7                       |
| Hispanic                                | 5.7                                | 13.4                       |
| Other                                   | 2.5                                | 5.3                        |
| Primary cause of renal failure (%)      |                                    |                            |
| Diabetes mellitus                       | 43.6                               | 45.8                       |
| Hypertension                            | 32.8                               | 29.4                       |
| GN                                      | 5.6                                | 8.0                        |
| Cystic kidney disease                   | 1.2                                | 1.9                        |
| Other                                   | 16.8                               | 14.8                       |
| Modality switching (%)                  |                                    |                            |
| HD to PD                                | 5.1                                | 6.3                        |
| PD to HD                                | 3.1                                | 3.6                        |
| HD, No change                           | 89.8                               | 86.2                       |
| PD, No change                           | 2.1                                | 3.8                        |
| Region (%)                              |                                    |                            |
| West                                    | 18.0                               | 19.9                       |
| Midwest                                 | 28.7                               | 21.3                       |
| South                                   | 38.3                               | 41.3                       |
| Northeast                               | 15.0                               | 17.5                       |
| Insurance status (%)                    |                                    |                            |
| Insuredb                                | 98.0                               | 93.2                       |
| Uninsuredb                              | 2.0                                | 6.8                        |
| First yr of dialysis (%)                |                                    |                            |
| 2005–2008                               | 34.1                               | 34.9                       |
| 2009–2012                               | 38.8                               | 36.5                       |
| 2013–2015                               | 27.1                               | 28.6                       |
| Comorbidities (%)                       |                                    |                            |
| Stroke                                  | 13.4                               | 9.2                        |
| Heart failure                           | 37.1                               | 31.5                       |
| Smoking                                 | 5.9                                | 6.3                        |
| Hypertension                            | 86.1                               | 85.9                       |
| Drug dependence                        | 0.6                                | 1.3                        |
| Peripheral vascular disease             | 17.1                               | 12.6                       |
| Coronary artery disease                 | 26.2                               | 19.1                       |
| Malignancy                              | 11.9                               | 7.4                        |
| Diabetes mellitus                       | 54.5                               | 55.3                       |

aIQR, interquartile range; HD, hemodialysis; PD, peritoneal dialysis.

bWhen compared with patients who did not discontinue dialysis, P for all categories <0.001.

bInsured comprises patients with both public and private insurance.
We also found an association between the calendar year of dialysis initiation and the risk of discontinuation, with patients who initiated dialysis in more recent years at higher risk of stopping dialysis outside of acute medical complication settings. Compared with patients who started dialysis between 2005 and 2008, those who initiated dialysis between 2009 and 2012 were 1.22 (1.18–1.25) times more likely to discontinue therapy. Patients who initiated dialysis between 2013 and 2015 had an even greater risk of discontinuation (HR, 1.61; 95% CI, 1.56 to 1.66).

Among those who did discontinue dialysis, 14,608 (50%) did so within 1.9 years of starting dialysis. Notably, Hispanic and non-Hispanic Black patients were less likely to discontinue therapy early compared with non-Hispanic White patients (HR, 0.27; 95% CI, 0.25 to 0.29 and HR, 0.31; 95% CI, 0.30 to 0.33, respectively). Similar to the overall cohort, patients who initiated dialysis in more recent years were more likely to stop dialysis earlier during treatment as compared with those beginning dialysis in 2005–2008 (all P<.01, Table 2). Finally, compared with patients treated exclusively with HD, patients who changed from HD to PD (HR, 0.74; 95% CI, 0.67 to 0.82) or were treated exclusively with PD (HR, 0.37; 95% CI, 0.33–0.41) were less likely to discontinue dialysis early during treatment.

### Table 2. Association between demographic factors and risk of discontinuation in the overall cohort and risk factors for early discontinuation

| Variable                                | Overall Cohort Hazard Ratio (95% Confidence Interval) | Early Discontinuationa Hazard Ratio (95% Confidence Interval) |
|-----------------------------------------|------------------------------------------------------|-------------------------------------------------------------|
| Treatment modality                      |                                                      |                                                             |
| PD only (versus HD only as reference)   | 0.45 (0.42 to 0.49)                                  | 0.37 (0.33 to 0.41)                                         |
| HD to PD (versus HD only as reference)  | 1.02 (0.97 to 1.07)                                  | 0.74 (0.67 to 0.82)                                         |
| PD to HD (versus PD only as reference)  | 2.73 (2.46 to 3.03)                                  | 3.22 (2.72 to 3.81)                                         |
| Age at dialysis onset (yr)              |                                                      |                                                             |
| 18–29                                   | Reference                                            |                                                             |
| 30–64                                   | 4.11 (3.25 to 5.20)                                  | 3.68 (2.55 to 5.32)                                         |
| ≥65                                     | 15.85 (12.54 to 20.03)                               | 14.63 (10.15 to 21.10)                                     |
| Sex                                     |                                                      |                                                             |
| Male                                    | Reference                                            | Reference                                                  |
| Female                                  | 1.16 (1.13 to 1.19)                                  | 1.17 (1.13 to 1.21)                                         |
| Race/Ethnicity                          |                                                      |                                                             |
| Non-Hispanic White                      | Reference                                            | Reference                                                  |
| Non-Hispanic Black                      | 0.32 (0.31 to 0.33)                                  | 0.31 (0.30 to 0.33)                                         |
| Hispanic                                | 0.29 (0.27 to 0.30)                                  | 0.27 (0.25 to 0.29)                                         |
| Other                                   | 0.30 (0.28 to 0.32)                                  | 0.27 (0.24 to 0.31)                                         |
| Region                                  |                                                      |                                                             |
| West                                    | Reference                                            | Reference                                                  |
| Midwest                                 | 1.16 (1.12 to 1.21)                                  | 1.12 (1.06 to 1.17)                                         |
| South                                   | 1.04 (1.01 to 1.08)                                  | 1.03 (0.98 to 1.08)                                         |
| Northeast                               | 0.77 (0.74 to 0.80)                                  | 0.71 (0.67 to 0.75)                                         |
| Median income in zip code               | 0.97 (0.97 to 0.98)                                  | 0.97 (0.96 to 0.98)                                         |
| Primary cause of renal failure          |                                                      |                                                             |
| Diabetes mellitus                       | Reference                                            | Reference                                                  |
| Hypertension                            | 1.04 (1.01 to 1.08)                                  | 1.12 (1.07 to 1.17)                                         |
| GN                                      | 0.81 (0.77 to 0.86)                                  | 0.89 (0.82 to 0.97)                                         |
| Cystic kidney disease                   | 0.67 (0.60 to 0.75)                                  | 0.52 (0.43 to 0.63)                                         |
| Other/Unknown cause                     | 1.02 (0.99 to 1.07)                                  | 1.35 (1.28 to 1.42)                                         |
| Yr of dialysis initiation               |                                                      |                                                             |
| 2005–2008                               | Reference                                            | Reference                                                  |
| 2009–2012                               | 1.22 (1.18 to 1.25)                                  | 1.16 (1.12 to 1.21)                                         |
| 2013–2015                               | 1.61 (1.56 to 1.66)                                  | 1.55 (1.49 to 1.62)                                         |
| Uninsured (versus Insured)              | 0.57 (0.53 to 0.62)                                  | 0.53 (0.46 to 0.61)                                         |
| Comorbidity (versus without condition)  |                                                      |                                                             |
| Stroke                                  | 1.42 (1.37 to 1.47)                                  | 1.46 (1.39 to 1.53)                                         |
| Diabetes mellitus                       | 1.01 (0.97 to 1.04)                                  | 0.96 (0.92 to 1.00)                                         |
| Hypertension                            | 0.92 (0.89 to 0.95)                                  | 0.83 (0.80 to 0.87)                                         |
| Heart failure                           | 1.20 (1.17 to 1.23)                                  | 1.28 (1.23 to 1.32)                                         |
| Coronary artery disease                 | 1.09 (1.06 to 1.12)                                  | 1.06 (1.02 to 1.11)                                         |
| Peripheral vascular disease             | 1.20 (1.16 to 1.24)                                  | 1.22 (1.16 to 1.27)                                         |
| Malignancy                              | 1.42 (1.37 to 1.48)                                  | 1.49 (1.42 to 1.56)                                         |
| Smoking                                 | 1.13 (1.07 to 1.18)                                  | 1.05 (0.98 to 1.13)                                         |
| Drug dependence                         | 1.03 (0.88 to 1.20)                                  | 1.31 (1.06 to 1.62)                                         |

PD, peritoneal dialysis; HD, hemodialysis.

*Analysis limited to 1.9 yr of follow-up (median time to discontinuation of dialysis for overall cohort).
Discussion

Dialysis discontinuation is a common end-of-life decision considered by patients with ESKD. In this study, we aimed to better characterize factors associated with this decision outside the context of acute medical complications. Similar to previously published studies that focused on inpatients who likely had an acute critical event (e.g., sepsis, myocardial infarction, stroke), we found that non-Hispanic White patients, women, and older patients had a higher risk of stopping dialysis outside of the context of acute medical complications during their usual state of health. We also found that patients who initiated dialysis in recent years were more likely to discontinue dialysis than those who initiated in the early 2000s, and they were more likely to stop dialysis early, which we defined as discontinuation within the first 2 years of starting kidney replacement therapy. We believe these findings are important given the results of a recent retrospective study, which used simulations to demonstrate that much of the observed ESKD-related mortality difference between ethnicities would be attenuated if dialysis discontinuation practices were to be more similar.

Our finding of a trend toward increasing early discontinuation of dialysis (Table 2) is notable, as the factors that are driving these trends are important to understand (8). Although the rate of palliative care utilization remains low, there is increasing education and awareness about the option of stopping dialysis, which may in part explain the increase in early discontinuation rates (9). It is also possible that patients who are less likely to thrive on dialysis or who have more comorbidities are being offered dialysis more frequently in recent years, and this subset subsequently decides to discontinue dialysis. Unlike in settings where an acute medical illness may precede the decision to stop dialysis, decisions made by patients outside of the acute setting may occur in the context of prolonged failure to thrive. Further research is needed to identify factors related to patients’ preferences, values, priorities, and quality-of-life considerations that may have led to the decision to stop dialysis. Additionally, the role for surrogate decision makers, spirituality, prognostic awareness, and decisional regret are all important factors that warrant further investigation.

Apart from the temporal trend in dialysis discontinuation, we also found that patients treated with PD had a lower risk of discontinuation compared with those treated with HD. In addition, those who converted from PD to HD had a higher risk of discontinuation compared with those who were treated exclusively with PD. Interestingly, this finding was absent among patients who converted from HD to PD. Data on differences in rates of dialysis discontinuation by treatment modality have been scarce, as many studies limit analyses to patients treated with either HD or PD exclusively. We believe our findings are unique in that they incorporate data from patients receiving either treatment modality, including patients who changed modalities. It is possible that PD provides better quality of life, and patients who are subsequently exposed to HD represent an especially high-risk group for a significant decline in quality of life (10,11). Whether maximizing the amount of time spent on PD in patients who have multiple comorbidities may decrease the likelihood of stopping chronic dialysis has not been examined and deserves further exploration.

The strengths of the study include the large size of a national cohort encompassing over one million patients and the ability to track changes in treatment modalities over time. Additionally, this nationally representative sample allows for generalization of our results to a broad US population. We do acknowledge some limitations of the study, including the retrospective nature of the study and the potential for residual confounding. Given that the CMS death notification form may be completed by nonmedical personnel, there is the potential for inaccurate coding (12–14). Additionally, the USRDS database does not have patient-identified reasons for deciding to stop dialysis, and we do not know definitively the reasons why PD patients discontinued treatment less often than HD patients, or why dialysis discontinuation rates have been increasing in more recent years. We are also unable to capture factors such as existential distress and spirituality (15). Qualitative or mixed-method studies may be needed to capture the true associations or drivers of this complex decision. Finally, we do not have data surrounding important factors such as decisional capacity, cognitive status, or the presence of frailty, dementia, or mental health comorbidities, all of which may play an important role in determining the likelihood of discontinuation of therapy.

In conclusion, the decision to discontinue dialysis among patients in nonacute settings is more common among those who initiated treatment more recently in our study, and is associated with a host of additional risk factors that deserve further investigation. In addition, factors associated with early discontinuation of dialysis in this population appear similar to those associated with discontinuation throughout their treatment course. Future multicenter studies that capture the granular reasons for why some patients decide to discontinue dialysis are needed to understand how to optimize the quality and delivery of palliative care when appropriate. This may equip kidney care teams with the ability to anticipate which patients are most likely to decide to discontinue therapy and ensure a patient-centered decision-making process.

Disclosures

All authors have nothing to disclose.

Funding

E. Ku was funded by National Heart, Lung, and Blood Institute grant K23 HL131023. K. Johansen was funded by National Institute of Diabetes and Digestive and Kidney Diseases grant K24 DK85153.

Acknowledgments

The data reported here have been supplied by the United States Renal Data System. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.

Author Contributions

C.E. McCulloch was responsible for the formal analysis, methodology, and writing review and editing. E. Ku was responsible for the conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, supervision, writing the original draft, and writing review and editing. K.L. Johansen was responsible for the formal analysis, methodology, and writing.
review and editing. M.J. Roberts was responsible for the conceptualization, formal analysis, investigation, methodology, writing the original draft, and writing review and editing. S. Coufal was responsible for the formal analysis, writing the original draft, and writing review and editing. T.P. Copeland was responsible for the data curation, formal analysis, investigation, methodology, supervision, writing the original draft, and writing review and editing. All authors contributed intellectual content during the writing and revision of the manuscript and accept accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

References

1. United States Renal Data System: 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2018

2. Chan S, Marshall MR, Ellis R, Ranganathan D, Hawley CM, Johnson DW, Wolley MJ: Haemodialysis withdrawal in Australia and New Zealand: A binational registry study. *Nephrol Dial Transplant* 35: 669–676, 2019 https://doi.org/10.1093/ndt/gfz160

3. Qazi HA, Chen H, Zhu M: Factors influencing dialysis withdrawal: A scoping review. *BMC Nephrol* 19: 96, 2018 https://doi.org/10.1186/s12882-018-0894-5

4. Wetmore JB, Yan H, Hu Y, Gilbertson DT, Liu J: Factors associated with withdrawal from maintenance dialysis: A case-control analysis. *Am J Kidney Dis* 71: 831–841, 2018 https://doi.org/10.1053/j.ajkd.2017.10.025

5. Cohen LM, Germain MJ, Poppell DM: Practical considerations in dialysis withdrawal: “To have that option is a blessing”. *JAMA* 289: 2113–2119, 2003 https://doi.org/10.1001/jama.289.16.2113

6. Scherer JS, Holley JL: The role of time-limited trials in dialysis decision making in critically ill patients. *Clin J Am Soc Nephrol* 11: 344–353, 2016 https://doi.org/10.2215/CJN.03550315

7. Moss AH: Revised dialysis clinical practice guideline promotes more informed decision-making. *Clin J Am Soc Nephrol* 5: 2380–2383, 2010 https://doi.org/10.2215/CJN.07108010

8. Agunbiade A, Dasgupta A, Ward AM: Racial/ethnic differences in dialysis discontinuation and survival after hospitalization for serious conditions among patients on maintenance dialysis. *J Am Soc Nephrol* 31: 149–160, 2020 https://doi.org/10.1681/ASN.2019020122

9. Wen Y, Jiang C, Koncicki HM, Horowitz CR, Cooper RS, Saha A, Coca SG, Nadkarni GN, Chan L: Trends and racial disparities of palliative care use among hospitalized patients with ESKD on dialysis. *J Am Soc Nephrol* 30: 1687–1696, 2019 https://doi.org/10.1681/ASN.2018121256

10. Dahlers C, Quinn M, Messersmith E, Lachance L, Subramanian L, Perry E, Cole J, Zhao J, Lee C, McCall M, Paulson L, Tenorio F: Patient perspectives on the choice of dialysis modality: Results from the Empowering Patients on Choices for Renal Replacement Therapy (EPOCH-RRT) study. *Am J Kidney Dis* 68: 901–910, 2016 https://doi.org/10.1053/j.ajkd.2016.05.010

11. Miskulin DC, Meyer KB, Athienites NV, Martin AA, Terrin N, Marsh JV, Fink NE, Coresh J, Powe NR, Klag MJ, Levey AS: Comorbidity and other factors associated with modality selection in incident dialysis patients: The CHOICE study. Choices for healthy outcomes in caring for end-stage renal disease. *Am J Kidney Dis* 39: 324–336, 2002 https://doi.org/10.1053/ajkd.2002.30552

12. Holley JL: A single-center review of the death notification form: Discontinuing dialysis before death is not a surrogate for withdrawal from dialysis. *Am J Kidney Dis* 40: 525–530, 2002 https://doi.org/10.1053/ajkd.2002.34910

13. Bhargava J, Germain M, Kitsen J, Cohen LM, Meyer KB: Knowledge and participation of front-line dialysis facility staff in end-of-life discussions. *Nephrol News Issues* 23: 34–36, 38–40, 2009

14. Murphy E, Germain MJ, Cairns H, Higginson IJ, Murtagh FE: International variation in classification of dialysis withdrawal: A systematic review. *Nephrol Dial Transplant* 29: 625–635, 2014 https://doi.org/10.1093/ndt/gft458

15. Schmidt RJ, Moss AH: Dying on dialysis: The case for a dignified withdrawal. *Clin J Am Soc Nephrol* 9: 174–180, 2014 https://doi.org/10.2215/CJN.05730513

Received: July 20, 2020 Accepted: December 9, 2020